Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Longitudinal growth retardation in a prepuberal girl with chronic myeloid leukemia on long-term treatment with imatinib.

Literature DB >> 19546438

Longitudinal growth retardation in a prepuberal girl with chronic myeloid leukemia on long-term treatment with imatinib.

Hansjoerg Schmid, Bernadette A S Jaeger, Judith Lohse, Meinolf Suttorp.

Abstract

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2009 PMID： 19546438 PMCID： PMC2719043 DOI： 10.3324/haematol.2009.008359

Source DB: PubMed Journal: Haematologica ISSN： 0390-6078 Impact factor: 9.941

× No keyword cloud information.

11 in total

1. Imatinib mesylate induces hypophosphatemia in patients with chronic myeloid leukemia in late chronic phase, and this effect is associated with response.

Authors: S Osorio; A García Noblejas; A Durán; J L Steegmann
Journal: Am J Hematol Date: 2007-05 Impact factor: 10.047

2. Increased cortical bone mineralization in imatinib treated patients with chronic myelogenous leukemia.

Authors: Sofia Jönsson; Bob Olsson; Claes Ohlsson; Mattias Lorentzon; Dan Mellström; Hans Wadenvik
Journal: Haematologica Date: 2008-05-27 Impact factor: 9.941

3. Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation.

Authors: F Millot; J Guilhot; B Nelken; T Leblanc; E S De Bont; A N Békassy; H Gadner; S Sufliarska; J Stary; H Gschaidmeier; F Guilhot; M Suttorp
Journal: Leukemia Date: 2006-02 Impact factor: 11.528

4. Altered bone and mineral metabolism in patients receiving imatinib mesylate.

Authors: Ellin Berman; Maria Nicolaides; Robert G Maki; Martin Fleisher; Suzanne Chanel; Kelly Scheu; Bri-Anne Wilson; Glenn Heller; Nicholas P Sauter
Journal: N Engl J Med Date: 2006-05-11 Impact factor: 91.245

Review 5. Pediatric reference intervals for bone markers.

Authors: Liju Yang; Vijaylaxmi Grey
Journal: Clin Biochem Date: 2006-01-19 Impact factor: 3.281

6. A cross-sectional study on biochemical parameters of bone turnover and vitamin d metabolites in healthy dutch children and young adults.

Authors: Inge M van der Sluis; Wim C Hop; Johannes P T M van Leeuwen; Huib A P Pols; Sabine M P F de Muinck Keizer-Schrama
Journal: Horm Res Date: 2002

7. Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms.

Authors: Susannah O'Sullivan; Dorit Naot; Karen Callon; Fran Porteous; Anne Horne; Diana Wattie; Maureen Watson; Jill Cornish; Peter Browett; Andrew Grey
Journal: J Bone Miner Res Date: 2007-11 Impact factor: 6.741

Review 8. Innovative approaches of targeted therapy for CML of childhood in combination with paediatric haematopoietic SCT.

Authors: M Suttorp
Journal: Bone Marrow Transplant Date: 2008-10 Impact factor: 5.483

9. Long-term imatinib therapy promotes bone formation in CML patients.

Authors: Stephen Fitter; Andrea L Dewar; Panagiota Kostakis; L Bik To; Timothy P Hughes; Marion M Roberts; Kevin Lynch; Barrie Vernon-Roberts; Andrew C W Zannettino
Journal: Blood Date: 2007-11-27 Impact factor: 22.113

10. Urinary pyridinoline and deoxypyridinoline in healthy children and in children with growth hormone deficiency.

Authors: S Fujimoto; T Kubo; H Tanaka; M Miura; Y Seino
Journal: J Clin Endocrinol Metab Date: 1995-06 Impact factor: 5.958

10 in total

1. Impact of the type of the BCR-ABL fusion transcript on the molecular response in pediatric patients with chronic myeloid leukemia.

Authors: Meinolf Suttorp; Christian Thiede; Josephine T Tauer; Ursula Range; Brigitte Schlegelberger; Nils von Neuhoff
Journal: Haematologica Date: 2010-02-09 Impact factor: 9.941

10. Micro-osmotic pumps for continuous release of the tyrosine kinase inhibitor bosutinib in juvenile rats and its impact on bone growth.

Authors: Josephine Tabea Tauer; Lorenz C Hofbauer; Rolang Jung; Reinhold G Erben; Meinolf Suttorp
Journal: Med Sci Monit Basic Res Date: 2013-11-04

10 in total

Longitudinal growth retardation in a prepuberal girl with chronic myeloid leukemia on long-term treatment with imatinib.

1. Imatinib mesylate induces hypophosphatemia in patients with chronic myeloid leukemia in late chronic phase, and this effect is associated with response.

2. Increased cortical bone mineralization in imatinib treated patients with chronic myelogenous leukemia.

3. Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation.

4. Altered bone and mineral metabolism in patients receiving imatinib mesylate.

Review 5. Pediatric reference intervals for bone markers.

6. A cross-sectional study on biochemical parameters of bone turnover and vitamin d metabolites in healthy dutch children and young adults.

7. Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms.

Review 8. Innovative approaches of targeted therapy for CML of childhood in combination with paediatric haematopoietic SCT.

9. Long-term imatinib therapy promotes bone formation in CML patients.

10. Urinary pyridinoline and deoxypyridinoline in healthy children and in children with growth hormone deficiency.

1. Impact of the type of the BCR-ABL fusion transcript on the molecular response in pediatric patients with chronic myeloid leukemia.

2. Philadelphia chromosome-positive acute lymphoblastic leukemia in childhood.

3. Pediatric chronic myeloid leukemia is a unique disease that requires a different approach.

4. How I treat childhood CML.

Review 5. Management of chronic myeloid leukemia in childhood.

Review 6. Endocrine side effects of broad-acting kinase inhibitors.

Review 7. Clinical review: kinase inhibitors: adverse effects related to the endocrine system.

8. The tyrosine kinase inhibitor dasatinib (SPRYCEL) inhibits chondrocyte activity and proliferation.

9. Changes in bone metabolic parameters in children with chronic myeloid leukemia on imatinib treatment.

10. Micro-osmotic pumps for continuous release of the tyrosine kinase inhibitor bosutinib in juvenile rats and its impact on bone growth.